Status:
UNKNOWN
Cardiac Biomarkers in Preeclampsia: Prediction of Disease and the Risk of Future Cardiovascular Events in Survivors
Lead Sponsor:
Babcock University
Conditions:
Preeclampsia
Eclampsia
Eligibility:
FEMALE
18-45 years
Brief Summary
SUMMARY Background: Improvements in the management and prevention of obstetric haemorrhage and sepsis, in addition to magnesium sulphate for preeclampsia have led to significant reduction in global ma...
Detailed Description
Preeclampsia is a disease that is strongly linked with the risk of stroke and other cardiovascular disease. This is a condition with greater prevalence in the Low and middle income countries of the wo...
Eligibility Criteria
Inclusion
- Healthy pregnant women at gestational age less than 20 weeks
- Women with diagnosis of preeclampsia at gestational age 20-41 weeks
- Healthy pregnant women without preeclampsia at gestational age 20-41 weeks
- Women less than one year postpartum with history of preeclampsia or eclampsia in index pregnancy
- Healthy women less than 1 year postpartum with no previous history of preeclampsia or eclampsia
Exclusion
- History of chronic hypertension or hypertension before pregnancy
- Patients with cardiac disease
- Patients with renal disease
- Patients with diabetes mellitus
- Patients with connective tissue disorders
Key Trial Info
Start Date :
December 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT04468763
Start Date
December 16 2019
End Date
November 30 2025
Last Update
July 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Babcock University Teaching Hospital
Sagamu, Ogun State, Nigeria, 121103